ArticleThe Journal of experimental medicine1995
Functional roles of the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DRA gene expression.
Article in The Journal of experimental medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas.Frontiers in medicine · 2015Review
- The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression.Molecular oncology · 2013Article
- Mechlorethamine-induced DNA-protein cross-linking in human fibrosarcoma (HT1080) cells.Journal of proteome research · 2011Article
- 7SK small nuclear RNA directly affects HMGA1 function in transcription regulation.Nucleic acids research · 2011Article
- HMGA1a recognition candidate DNA sequences in humans.PloS one · 2009Article
- Novel mechanisms of class II major histocompatibility complex gene regulation.Immunologic research · 2003Review
- Murine NFX.1: isolation and characterization of its messenger RNA, mapping of its chromosomal location and assessment of its developmental expression.Immunology · 2002Article
- The HMG I proteins: dynamic roles in gene activation, development, and tumorigenesis.Immunologic research · 2001Review
- High-mobility-group protein I can modulate binding of transcription factors to the U5 region of the human immunodeficiency virus type 1 proviral promoter.Journal of virology · 2000Article
- The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2000Article
- CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.Genes & development · 2000Article
- Warner-Lambert/Parke-Davis Award lecture. Many tumors and many genes: genetics of uterine leiomyomata.The American journal of pathology · 1998Review
- NF-kappaB mediated transcriptional activation is enhanced by the architectural factor HMGI-C.Nucleic acids research · 1998Article
- Article
- Intra- and intermolecular cooperative binding of high-mobility-group protein I(Y) to the beta-interferon promoter.Molecular and cellular biology · 1997Article
- HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm.The American journal of pathology · 1997Article
- Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.Molecular and cellular biology · 1997Article
- Multivalent DNA-binding properties of the HMG-1 proteins.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The class II major histocompatibility complex gene HLA-DRA is expressed in B cells, activated T lymphocytes, and in antigen-presenting cells. In addition, HLA-DRA gene expression is inducible in a variety of cell types by interferon-gamma (IFN-gamma). Here we show that the lymphoid-specific transcription factor Oct-2A plays a critical role in HLA-DRA gene expression in class II-positive B cell lines, and that the high mobility group protein (HMG) I/Y binds to multiple sites within the DRA promoter, including the Oct-2A binding site. Coexpression of HMG I/Y and Oct-2 in cell lines lacking Oct-2 results in high levels of HLA-DRA gene expression, and in vitro DNA-binding studies reveal that HMG I/Y stimulates Oct-2A binding to the HLA-DRA promoter. Thus, Oct-2A and HMG I/Y may synergize to activate HLA-DRA expression in B cells. By contrast, Oct-2A is not involved in the IFN-gamma induction of the HLA-DRA gene in HeLa cells, but antisense HMG I/Y dramatically decreases the level of induction. We conclude that distinct sets of transcription factors are involved in the two modes of HLA-DRA expression, and that HMG I/Y may be important for B cell-specific expression, and is essential for IFN-gamma induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.